Generic placeholder image

Infectious Disorders - Drug Targets

Author(s): Sushil kumar Singh and Shyam Sundar Pancholi*

DOI: 10.2174/0118715265307531240801091445

DownloadDownload PDF Flyer Cite As
Role of Posaconazole Drug in the Treatment of Invasive Fungal Disease: A Review

Article ID: e18715265307531 Pages: 10

  • * (Excluding Mailing and Handling)

Explore Articles
About Journal
For Authors
For Editors
For Reviewers

Abstract

Posaconazole is an antifungal medication used primarily to treat invasive fungal infections caused by various organisms, such as Aspergillus, Candida, and certain molds. It belongs to the class of drugs known as triazole antifungals. Clinical studies have reported posaconazole to be effective in treating various invasive fungal infections, especially in patients who are immunocompromised, such as those with weakened immune systems due to conditions like HIV/AIDS, undergoing chemotherapy, or having received an organ transplant. It has effectively treated invasive candidiasis, aspergillosis, zygomycosis, and other serious fungal infections. The effectiveness of the drug varies based on factors, such as the type of infection, the patient's immune status, and the site of infection. This review describes the types of infection, the drug's safety profile, the development of resistance to posaconazole, and strategies to manage or prevent resistance.

Keywords: Posaconazole, fungal disease, treatment, candidiasis, aspergillosis, zygomycosis.

Graphical Abstract

[1]
Viegas C, Pinheiro AC, Sabino R, Viegas S, Brandão J, Veríssimo C, Eds. Environmental mycology in public health: Fungi and mycotoxins risk assessment and management. Academic Press 2015.
[2]
Bongomin F, Ekeng BE, Kibone W, et al. Invasive fungal diseases in Africa: A critical literature review. J Fungi 2022; 8(12): 1236.
[http://dx.doi.org/10.3390/jof8121236] [PMID: 36547569]
[3]
Kumar S, Jain T, Banerjee D. Fungal diseases and their treatment: A holistic approach. In: Pathogenicity and Drug Resistance of Human Pathogens: Mechanisms and Novel Approaches. Springer 2019; pp. 111-34.
[http://dx.doi.org/10.1007/978-981-32-9449-3_6]
[4]
Chen SCA, Slavin MA. Management of mucorales infections in transplant patients. In: Emerging Transplant Infections. Cham: Springer 2020.
[http://dx.doi.org/10.1007/978-3-030-01751-4_45-1]
[5]
Jordá T, Puig S. Regulation of ergosterol biosynthesis in Saccharomyces cerevisiae. Genes 2020; 11(7): 795.
[http://dx.doi.org/10.3390/genes11070795] [PMID: 32679672]
[6]
Maertens JA, Rahav G, Lee DG, et al. Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: A phase 3, randomised, controlled, non-inferiority trial. Lancet 2021; 397(10273): 499-509.
[http://dx.doi.org/10.1016/S0140-6736(21)00219-1] [PMID: 33549194]
[7]
Chen X, Wang J, Wang S, et al. Real-world assessment of the effectiveness of posaconazole for the prophylaxis and treatment of invasive fungal infections in hematological patients. Medicine 2021; 100(30): e26772.
[http://dx.doi.org/10.1097/MD.0000000000026772] [PMID: 34397725]
[8]
Abuhelwa AY, Williams DB, Upton RN, Foster DJR. Food, gastrointestinal pH, and models of oral drug absorption. Eur J Pharm Biopharm 2017; 112: 234-48.
[http://dx.doi.org/10.1016/j.ejpb.2016.11.034] [PMID: 27914234]
[9]
Zono B. Molecular analysis of cryptococcus spp. Reveals species diversity and multilocus sequence typing heterogeneity among people living with HIV in kinshasa. J Fungi 2021; 7(916)
[10]
Scott IA, Hilmer SN, Reeve E, et al. Reducing inappropriate polypharmacy: The process of deprescribing. JAMA Intern Med 2015; 175(5): 827-34.
[http://dx.doi.org/10.1001/jamainternmed.2015.0324] [PMID: 25798731]
[11]
Müller C, Neugebauer T, Zill P, Lass-Flörl C, Bracher F, Binder U. Sterol composition of clinically relevant mucorales and changes resulting from posaconazole treatment. Molecules 2018; 23(5): 1218.
[http://dx.doi.org/10.3390/molecules23051218] [PMID: 29783739]
[12]
Ahmed M Z, Rao T, Saeed A, et al. Antifungal drugs: Mechanism of action and resistance. Biochemistry of Drug Resistance 143-65.
[13]
Jacquier N, Schneiter R. Mechanisms of sterol uptake and transport in yeast. J Steroid Biochem Mol Biol 2012; 129(1-2): 70-8.
[http://dx.doi.org/10.1016/j.jsbmb.2010.11.014] [PMID: 21145395]
[14]
Ke CL, Deng FS, Chuang CY, Lin CH. Antimicrobial actions and applications of chitosan. Polymers 2021; 13(6): 904.
[http://dx.doi.org/10.3390/polym13060904] [PMID: 33804268]
[15]
Karaburun AÇ, Kaya Çavuşoğlu B, Acar Çevik U, et al. Synthesis and antifungal potential of some novel benzimidazole-1, 3, 4-oxadiazole compounds. Molecules 2019; 24(1): 191.
[http://dx.doi.org/10.3390/molecules24010191] [PMID: 30621357]
[16]
Morris MI. Posaconazole: A new oral antifungal agent with an expanded spectrum of activity. Am J Health Syst Pharm 2009; 66(3): 225-36.
[http://dx.doi.org/10.2146/ajhp070532] [PMID: 19179636]
[17]
Wal P, Saraswat N, Vig H. A detailed insight onto the molecular and cellular mechanism of action of the antifungal drugs used in the treatment of superficial fungal infections. Curr Drug Ther 2022; 17(3): 148-59.
[http://dx.doi.org/10.2174/1574885517666220328141054]
[18]
Cortés JCG, Curto MÁ, Carvalho VSD, Pérez P, Ribas JC. The fungal cell wall as a target for the development of new antifungal therapies. Biotechnol Adv 2019; 37(6): 107352.
[http://dx.doi.org/10.1016/j.biotechadv.2019.02.008] [PMID: 30797093]
[19]
Hamperl S, Cimprich KA. Conflict resolution in the genome: How transcription and replication make it work. Cell 2016; 167(6): 1455-67.
[http://dx.doi.org/10.1016/j.cell.2016.09.053] [PMID: 27912056]
[20]
Riquelme M, Aguirre J, Bartnicki-García S, et al. Fungal morphogenesis, from the polarized growth of hyphae to complex reproduction and infection structures. Microbiol Mol Biol Rev 2018; 82(2): e00068-17.
[http://dx.doi.org/10.1128/MMBR.00068-17] [PMID: 29643171]
[21]
Guntuku L, Naidu VGM, Ganesh Yerra V. Mitochondrial dysfunction in gliomas: Pharmacotherapeutic potential of natural compounds. Curr Neuropharmacol 2016; 14(6): 567-83.
[http://dx.doi.org/10.2174/1570159X14666160121115641] [PMID: 26791479]
[22]
Ibe C, Munro CA. Fungal cell wall proteins and signaling pathways form a cytoprotective network to combat stresses. J Fungi 2021; 7(9): 739.
[http://dx.doi.org/10.3390/jof7090739] [PMID: 34575777]
[23]
Li J, Nguyen C, Garcia-Diaz J. Role of new antifungal agents in the treatment of invasive fungal infections in transplant recipients: isavuconazole and new posaconazole formulations. J Fungi 2015; 1(3): 345-66.
[http://dx.doi.org/10.3390/jof1030345] [PMID: 29376915]
[24]
Soysal A. Prevention of invasive fungal infections in immunocompromised patients: The role of delayed-release posaconazole. Infect Drug Resist 2015; 8: 321-31.
[http://dx.doi.org/10.2147/IDR.S65592] [PMID: 26392781]
[25]
Auberger J, Lass-Flörl C, Aigner M, Clausen J, Gastl G, Nachbaur D. Invasive fungal breakthrough infections, fungal colonization and emergence of resistant strains in high-risk patients receiving antifungal prophylaxis with posaconazole: real-life data from a single-centre institutional retrospective observational study. J Antimicrob Chemother 2012; 67(9): 2268-73.
[http://dx.doi.org/10.1093/jac/dks189] [PMID: 22653819]
[26]
Wong TY, Loo YS, Veettil SK, et al. Efficacy and safety of posaconazole for the prevention of invasive fungal infections in immunocompromised patients: A systematic review with meta-analysis and trial sequential analysis. Sci Rep 2020; 10(1): 14575.
[http://dx.doi.org/10.1038/s41598-020-71571-0] [PMID: 32884060]
[27]
Gupta AK, Talukder M, Venkataraman M. Review of the alternative therapies for onychomycosis and superficial fungal infections: Posaconazole, fosravuconazole, voriconazole, oteseconazole. Int J Dermatol 2022; 61(12): 1431-41.
[http://dx.doi.org/10.1111/ijd.15999] [PMID: 34882787]
[28]
Drew RH, Townsend ML, Pound MW, Johnson SW, Perfect JR. Recent advances in the treatment of life-threatening, invasive fungal infections. Expert Opin Pharmacother 2013; 14(17): 2361-74.
[http://dx.doi.org/10.1517/14656566.2013.838217] [PMID: 24050675]
[29]
Leung S, Poulakos M, Machin J. Posaconazole: An update of its clinical use. Pharmacy 2015; 3(4): 210-68.
[http://dx.doi.org/10.3390/pharmacy3040210] [PMID: 28975914]
[30]
Leventakos K, Lewis RE, Kontoyiannis DP. Fungal infections in leukemia patients: How do we prevent and treat them? Clin Infect Dis 2010; 50(3): 405-15.
[http://dx.doi.org/10.1086/649879] [PMID: 20047485]
[31]
Allen D, Wilson D, Drew R, Perfect J. Azole antifungals: 35 years of invasive fungal infection management. Expert Rev Anti Infect Ther 2015; 13(6): 787-98.
[http://dx.doi.org/10.1586/14787210.2015.1032939] [PMID: 25843556]
[32]
Aperis G, Alivanis P. Posaconazole: A new antifungal weapon. Rev Recent Clin Trials 2011; 6(3): 204-19.
[http://dx.doi.org/10.2174/157488711796575595] [PMID: 21682687]
[33]
Kumar Nigam P. Antifungal drugs and resistance: Current concepts. Nasza Dermatol Online 2015; 6(2): 212-21.
[http://dx.doi.org/10.7241/ourd.20152.58]
[34]
Lamoth F, Kontoyiannis DP. Therapeutic challenges of non-Aspergillus invasive mold infections in immunosuppressed patients. Antimicrob Agents Chemother 2019; 63(11): e01244-19.
[http://dx.doi.org/10.1128/AAC.01244-19] [PMID: 31481441]
[35]
Frampton JE, Scott LJ. Posaconazole. Drugs 2008; 68(7): 993-1016.
[http://dx.doi.org/10.2165/00003495-200868070-00008] [PMID: 18457464]
[36]
Volberding PA, Deeks SG. Antiretroviral therapy and management of HIV infection. Lancet 2010; 376(9734): 49-62.
[http://dx.doi.org/10.1016/S0140-6736(10)60676-9] [PMID: 20609987]
[37]
Karthaus M. Prophylaxis and treatment of invasive aspergillosis with voriconazole, posaconazole and caspofungin - Review of the literature. Eur J Med Res 2011; 16(4): 145-52.
[http://dx.doi.org/10.1186/2047-783X-16-4-145] [PMID: 21486728]
[38]
Wang J, Zhou M, Xu JY, Zhou RF, Chen B, Wan Y. Comparison of antifungal prophylaxis drugs in patients with hematological disease or undergoing hematopoietic stem cell transplantation: A systematic review and network meta-analysis. JAMA Netw Open 2020; 3(10): e2017652.
[http://dx.doi.org/10.1001/jamanetworkopen.2020.17652] [PMID: 33030550]
[39]
Pasula S, Chandrasekar PH. Azole resistance in Aspergillus species: promising therapeutic options. Expert Opin Pharmacother 2021; 22(15): 2071-8.
[http://dx.doi.org/10.1080/14656566.2021.1940134] [PMID: 34129410]
[40]
Lamoth F, Calandra T. Pulmonary aspergillosis: Diagnosis and treatment. Eur Respir Rev 2022; 31(166): 220114.
[http://dx.doi.org/10.1183/16000617.0114-2022] [PMID: 36450372]
[41]
Varaiya A, Sundaresan A. Emerging mucormycosis: Problems and treatments. In: Fungi and Fungal Products in Human Welfare and Biotechnology. Singapore: Springer Nature Singapore 2023; pp. 97-125.
[http://dx.doi.org/10.1007/978-981-19-8853-0_4]
[42]
Walther G, Wagner L, Kurzai O. Updates on the taxonomy of Mucorales with an emphasis on clinically important taxa. J Fungi 2019; 5(4): 106.
[http://dx.doi.org/10.3390/jof5040106] [PMID: 31739583]
[43]
Logan A, Wolfe A, Williamson JC. Antifungal resistance and the role of new therapeutic agents. Curr Infect Dis Rep 2022; 24(9): 105-16.
[http://dx.doi.org/10.1007/s11908-022-00782-5] [PMID: 35812838]
[44]
Hoenigl M, Sprute R, Egger M, et al. The antifungal pipeline: Fosmanogepix, ibrexafungerp, olorofim, opelconazole, and rezafungin. Drugs 2021; 81(15): 1703-29.
[http://dx.doi.org/10.1007/s40265-021-01611-0] [PMID: 34626339]
[45]
Al Yazidi LS, Al-Hatmi AMS. Fusariosis: An update on therapeutic options for management. Expert Opin Orphan Drugs 2021; 9(3): 95-103.
[http://dx.doi.org/10.1080/21678707.2021.1904394]
[46]
Heidrich D, Pagani DM, Koehler A, Alves KO, Scroferneker ML. Effect of melanin biosynthesis inhibition on the antifungal susceptibility of chromoblastomycosis agents. Antimicrob Agents Chemother 2021; 65(8): e00546-21.
[http://dx.doi.org/10.1128/AAC.00546-21] [PMID: 33972246]
[47]
Huang C, Zhang Y, Song Y, Wan Z, Wang X, Li R. Phaeohyphomycosis caused by Phialophora americana with CARD9 mutation and 20‐year literature review in China. Mycoses 2019; 62(10): 908-19.
[http://dx.doi.org/10.1111/myc.12962] [PMID: 31271673]
[48]
Seyedmousavi S, Chang YC, Youn JH, et al. In vivo efficacy of olorofim against systemic scedosporiosis and lomentosporiosis. Antimicrob Agents Chemother 2021; 65(10): e00434-21.
[http://dx.doi.org/10.1128/AAC.00434-21] [PMID: 34252298]
[49]
Schwartz IS, Kauffman CA. Blastomycosis. Semin Respir Crit Care Med 2020; 41(1): 31-41.
[50]
Hanzlicek AS. KuKanich KS, Cook AK, et al Clinical utility of fungal culture and antifungal susceptibility in cats and dogs with histoplasmosis. J Vet Intern Med 2023; 37(3): 998-1006.
[http://dx.doi.org/10.1111/jvim.16725] [PMID: 37092675]
[51]
Chen L, Krekels EHJ, Heijnen AR, Knibbe CAJ, Brüggemann RJ. An integrated population pharmacokinetic analysis for posaconazole oral suspension, delayed-release tablet, and intravenous infusion in healthy volunteers. Drugs 2023; 83(1): 75-86.
[http://dx.doi.org/10.1007/s40265-022-01819-8] [PMID: 36607589]
[52]
Phillips NA, Bachmann G, Haefner H, Martens M, Stockdale C. Topical treatment of recurrent vulvovaginal candidiasis: An expert consensus. Women’s. Women’s. Health Rep 2022; 3(1): 38-42.
[http://dx.doi.org/10.1089/whr.2021.0065] [PMID: 35136875]
[53]
Kamath S, Kumar M, Sarkar N, Ahmed T, Sunder A. Study of profile of mucormycosis during the second wave of COVID-19 in a tertiary care hospital. Cureus 2022; 14(1): e21054.
[http://dx.doi.org/10.7759/cureus.21054] [PMID: 35155019]
[54]
Chen L, Krekels EHJ, Verweij PE, Buil JB, Knibbe CAJ, Brüggemann RJM. Pharmacokinetics and pharmacodynamics of posaconazole. Drugs 2020; 80(7): 671-95.
[http://dx.doi.org/10.1007/s40265-020-01306-y] [PMID: 32323222]
[55]
Ding Q, Huang S, Sun Z, Chen K, Li X, Pei Q. A review of population pharmacokinetic models of posaconazole. Drug Des Devel Ther 2022; 16: 3691-709.
[http://dx.doi.org/10.2147/DDDT.S384637] [PMID: 36277600]
[56]
Van Daele R, Spriet I, Maertens J. Posaconazole in prophylaxis and treatment of invasive fungal infections: A pharmacokinetic, pharmacodynamic and clinical evaluation. Expert Opin Drug Metab Toxicol 2020; 16(7): 539-50.
[http://dx.doi.org/10.1080/17425255.2020.1764939] [PMID: 32478597]
[57]
Echeverria-Esnal D, Martín-Ontiyuelo C, Navarrete-Rouco ME, et al. Pharmacological management of antifungal agents in pulmonary aspergillosis: An updated review. Expert Rev Anti Infect Ther 2022; 20(2): 179-97.
[http://dx.doi.org/10.1080/14787210.2021.1962292] [PMID: 34328373]
[58]
Beck KR, Telisman L, van Koppen CJ, Thompson GR III, Odermatt A. Molecular mechanisms of posaconazole- and itraconazole-induced pseudohyperaldosteronism and assessment of other systemically used azole antifungals. J Steroid Biochem Mol Biol 2020; 199: 105605.
[http://dx.doi.org/10.1016/j.jsbmb.2020.105605] [PMID: 31982514]
[59]
Waalewijn H, Turkova A, Rakhmanina N, et al. Optimizing pediatric dosing recommendations and treatment management of antiretroviral drugs using therapeutic drug monitoring data in children living with HIV. Ther Drug Monit 2019; 41(4): 431-43.
[http://dx.doi.org/10.1097/FTD.0000000000000637] [PMID: 31008997]
[60]
Brandt C, Atkinson TJ. A review of the safety of buprenorphine in special populations. Am J Med Sci 2022; 364(6): 675-84.
[http://dx.doi.org/10.1016/j.amjms.2022.06.025] [PMID: 35843298]
[61]
Czajka KM, Venkataraman K, Brabant-Kirwan D, et al. Molecular mechanisms associated with antifungal resistance in pathogenic Candida species. Cells 2023; 12(22): 2655.
[http://dx.doi.org/10.3390/cells12222655] [PMID: 37998390]
[62]
Vitiello A, Ferrara F, Boccellino M, et al. Antifungal drug resistance: An emergent health threat. Biomedicines 2023; 11(4): 1063.
[http://dx.doi.org/10.3390/biomedicines11041063] [PMID: 37189681]
[63]
Douglas AP, Smibert OC, Bajel A, et al. Consensus guidelines for the diagnosis and management of invasive aspergillosis, 2021. Intern Med J 2021; 51(S7) (Suppl. 7): 143-76.
[http://dx.doi.org/10.1111/imj.15591] [PMID: 34937136]
[64]
Geddes-McAlister J, Shapiro RS. New pathogens, new tricks: Emerging, drug‐resistant fungal pathogens and future prospects for antifungal therapeutics. Ann N Y Acad Sci 2019; 1435(1): 57-78.
[http://dx.doi.org/10.1111/nyas.13739] [PMID: 29762860]
[65]
Fisher MC, Alastruey-Izquierdo A, Berman J, et al. Tackling the emerging threat of antifungal resistance to human health. Nat Rev Microbiol 2022; 20(9): 557-71.
[http://dx.doi.org/10.1038/s41579-022-00720-1] [PMID: 35352028]
[66]
Trikha G, Nucci M, Wingard JR, Safdar A. Antimicrobial drug prophylaxis: Challenges and controversies. In: Principles and Practice of Transplant Infectious Diseases. New York, NY: Springer 2019.
[67]
Risum M, Datcu R, Johansen HK, Schønheyder H, Rosenvinge FS, Knudsen IJD. Update 2016-2018 of the nationwide Danish fungaemia surveillance study: Epidemiologic changes in a 15-year perspective. J Fungi 2019; 5(4): 94-6.
[PMID: 31591307]